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Summary. Background: Platelet activation is an energydependent process, but the type and integrated use of metabolic fuels required to drive activation remain unclear. Objective: To dissect the metabolic fuel and pathway plasticity required for platelet activation. Methods: Platelet oxygen consumption rate and extracellular acidification rate were measured as markers of oxidative phosphorylation (OXPHOS) and glycolysis, respectively. Glucose and glycogen were quantified by enzyme-coupled fluorometric assay. Results: Blood platelets switched freely between glycolysis and OXPHOS, using either glucose or fatty acids at rest. The transition of platelets from a quiescent to an activated state promoted rapid uptake of exogenous glucose, associated with a shift to a predominantly glycolytic phenotype coupled with a minor rise in mitochondrial oxygen consumption. Consistent with this metabolic plasticity, under nutrient-limiting conditions, platelets utilized glucose, glycogen or fatty acids independently to support activation. Importantly, the glycolytic switch occurred even in the absence of extracellular glucose, originating from endogenous glycogen. Focusing on the relative flexibility of mitochondrial fuel oxidation of glucose and fatty acids, we found that inhibition of oxidation of a single fuel was compensated for by increased oxidation of the other, but, when oxidation was inhibited, glycolysis was upregulated. Glutamine made little contribution to mitochondrial oxygen consumption. Analysis of platelet functional dependency on ATP from different pathways demonstrated that inhibition of both fuel oxidation and glycolysis were required to prevent agonist-driven platelet activation. Conclusion:
Introduction
Blood platelets play a critical role in the cessation of bleeding upon vascular injury. Exposure of subendothelial matrix proteins at areas of vessel wall damage triggers platelet activation, adhesion, and aggregation. The subsequent release of soluble platelet agonists triggers platelet aggregation to ensure rapid hemostasis. Conversely, the inappropriate activation of platelets can promote vascular inflammation, atherogenesis, and arterial thrombosis [1, 2] . The transition of platelets from a quiescent to an activated state requires dramatic changes in the availability of ATP [3] [4] [5] [6] [7] . Early studies used [6] [7] [8] [9] [10] [11] [12] [13] [14] C]glucose to confirm that platelets possess the molecular machinery necessary to generate ATP through both glycolysis and oxidative phosphorylation (OXPHOS) of glucose [8, 9] . These early data have now been confirmed by modern metabolic analysis [10] , which has provided an important framework for understanding platelet metabolism. Although platelets express glucose transporters, and glucose is an established metabolic substrate, platelets also have the capacity to take up and oxidize fatty acids (FAs) [11] and glutamine as sources of ATP generation at rest and in response to activatory stimuli [10] . Despite this, our knowledge of platelet metabolism remains incomplete, as the contribution of internal stores of glycogen has been overlooked. This knowledge is crucial, because regulation of metabolic pathways is influenced by the relative abundance of glucose, FAs, glutamine, and internal stores of energy, and the ability of cells to access, and switch between, these substrates. Thus, although platelets have the potential for metabolic flexibility, we have only a partial understanding of fuel choices made by platelets and whether these are functionally specific. Similarly, although platelet mitochondrial dysfunction has been reported in a number of disorders, including type 2 diabetes [12, 13] , sickle cell disease, and sepsis [14, 15] , the overall importance to, and flexibility of mitochondria in, platelet function remains poorly understood. To address this knowledge gap, we examined whether platelet activation was associated with regulated changes in fuel metabolism, which, in turn, were linked to specific functional responses. Crucially, we explored the extent to which endogenous reserves of fuel, in the form of glycogen, contribute to platelet metabolic function.
Materials and methods

Reagents
Studies were approved by the Hull York Medical School Ethics Committee, and were conducted in accordance with the Declaration of Helsinki. Antimycin A from Streptomyces (antimycin A), rotenone and Cell-Tak Cell & Tissue Adhesive were from Scientific Laboratory Supplies Limited (Hessle, UK). Glucose standard (5 mmol L À1 ) was from Analox (Stourbridge, UK).
NADP+ and hexokinase/glucose-6-phosphate dehydrogenase were from Roche (Welwyn Garden City, UK). Collagen Reagent HORM Suspension was from Takeda Cambridge (Cambridge, UK). All other chemicals were from Sigma-Aldrich (Dorset, UK).
Platelet isolation and aggregation
Human washed platelets were prepared, and aggregation and ATP secretion were tested, as described previously [16] . For experiments in glucose-restricted medium, glucose was excluded from modified Tyrode's buffer. For metabolic analyses, platelets were prepared as described previously [17] , and then diluted to 1 9 10 8 mL À1 in modified Tyrode's buffer (15 mM NaCl, 0.55 mM NaH 2 PO 4 , 2.7 mM KCl, 0.5 mM MgCl 2 , and 3 mg L À1 phenol red).
Glucose consumption by platelets in vitro
Washed platelets (2.5 9 10 8 mL À1 ) were stimulated with thrombin (0.01-0.1 U mL À1 ), and aliquots were removed at 0, 1, 3, 5, 7 and 9 min for glucose analysis with an enzyme-coupled fluorometric assay modified from [18] . Briefly, the conversion of glucose to phosphoglucono-dlactone results in the production of highly fluorescent NADPH. The change in fluorescence is proportional to the amount of glucose, which can be detected with a fluorescence microplate reader with excitation/emission of 340/460 nm.
Measuring platelet oxygen consumption and glycolytic rate
The XFp format Seahorse extracellular flux analyser (Agilent Technologies UK LDA Ltd, Stockport, UK) was used to measure the platelet oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). XFp microplates were coated with Cell-Tak [17] , washed with phosphate-buffered saline, and dried 30 min prior to experiments. Washed platelets (1 9 10 8 mL À1 ; 50 lL)
were seeded onto the plate as described previously [17] . Glucose:
Platelet glycogen content, at rest and after thrombin stimulation, was determined in glucose-depleted Tyrode's buffer with the acid hydrolysis method [19] . Briefly, platelet samples were subjected to sonication to release all of the glycogen. The supernatant was acid-hydrolyzed with 4 M HCl, and boiled for 90 min before being neutralized with 2 M Na 2 CO 3 . The liberated glucose was quantified with an enzyme-coupled fluorometric assay.
Statistical analysis
Student's t-test and ANOVA followed by either Dunn's multiple comparison test or the Holm-Sidak multiple comparison test were used. Non-linear regression (doseresponse curve) was used to compare the concentrations of agonists (EC 50 ) giving half of the maximal response. Data are presented as mean AE standard error of the mean for assays with three technical replicates per biological replicate, or as mean AE standard deviation for three biological replicates. All statistical analyses were performed with GRAPHPAD PRISM.
Results
Thrombin-induced platelet activation stimulates glucose uptake
Thrombin stimulation induced rapid glucose depletion from the platelet containing-medium (Fig. 1) Fig. 1Ai ,ii), before returning to basal levels 3 min after stimulation (Fig. 1Ai,ii) . Using a concentration of thrombin (0.01 U mL À1 ) to induce a threshold aggregation response, we observed biphasic depletion of glucose that was linked to the aggregation response (Fig. 1Bi,ii) . (Fig. 1Bi,ii) . The rate of glucose depletion for the secondary aggregation response (5-7 min) was significantly higher (P < 0.05) than that for the initial aggregation response (1-3 min). These data suggest that thrombin-induced platelet activation stimulates dose-dependent glucose uptake, which coincides with the different phases of the aggregation response (Fig. 1A,B) . To confirm this link between platelet function and glucose metabolism, we measured the ECAR as a readout of glycolysis. Thrombin stimulated glycolysis, as shown by a transient increase in the ECAR (P < 0.0001; Fig. 1Ci ,ii). Inhibition of thromboxane A 2 (TxA 2 ) generation by indomethacin caused a modest but significant reduction in ECAR (4.2 AE 0.7 to 3.4 AE 0.6 mpH min À1 lg À1 protein; P < 0.05). In contrast, inhibition of ADP signaling with apyrase was without effect. These data suggest that platelets actively take up external glucose in response to physiological stimuli that drive energy-demanding functions.
Thrombin-induced maximal glycolytic capacity requires both protease-activated receptor (PAR) 1 and PAR4
We next examined the maximal glycolytic capacity [20] of platelets (maximal rate of conversion of glucose to lactate under stressed conditions), at rest and during activation, with the XFp glycolytic stress test. The basal ECAR was increased to 1.63 AE 0.6 mpH min À1 lg À1 protein (P < 0.01) with glucose addition (5.6 mM), giving the basal glycolytic function (Fig. 2Ai,ii) . The injection of oligomycin, to inhibit all mitochondrial ATP generation, increased the ECAR to 4.0 AE 0.2 mpH min À1 lg À1 protein (P < 0.001), which was taken as maximal glycolysis in resting platelets. The addition of 2-DG abolished the ECAR, indicating that the ECAR resulted from glycolysis, and that the non-glycolytic ECAR was negligible (Fig. 2Ai ,ii). Stimulation with thrombin (0.1 U mL
À1
) (in the presence of glucose) caused a 10-fold increase in the ECAR (5.9 AE 0.4 mpH min À1 lg À1 protein; P < 0.001) (Fig. 2Bi,ii) , which began to fall over the next 25 min. The subsequent treatment with oligomycin increased the ECAR to 5.43 AE 0.4 mpH min À1 lg À1 protein. As this increase was no different from that induced by thrombin, it suggested that thrombin induced maximal glycolytic capacity. Thrombin activation of platelets requires ligation of both PAR1 and PAR4 [21] , so we next examined their relative contributions to platelet glycolytic capacity (Fig. S2A,B) . PAR1-specific and PAR4-specific peptides Fatty acids:
%Flexibility ¼ %Capacity À %Dependency induced dose-dependent glycolytic responses (Fig. 2C,D) . However, neither peptide stimulated the ECAR to the same extent as thrombin at maximal doses. Consistent with these observations, oligomycin was able to increase the ECAR further in the presence of both PAR1 (5.8 AE 0.1 mpH min À1 lg À1 protein; P < 0.001) and PAR4 (4.0 AE 0.1 mpH min À1 lg À1 protein; P < 0.001).
These data suggest that platelets have sufficient glycolytic Inhibition of mitochondrial ATP synthesis with oligomycin increased glycolysis (Fig. 2) , suggesting that OXPHOS contributes to ATP generation. Therefore, we examined the partitioning of glucose to glycolysis and OXPHOS. To create conditions in which the OCR and ECAR were mostly glucose-dependent, platelets were treated with etomoxir, an inhibitor of carnitine palmitoyltransferase-1 [10, 22] , to eliminate the contribution of FA b-oxidation to the OCR. After stimulation with thrombin (0.1 U mL À1 ), the OCR increased from 1.3 AE 0.02 to 2.0 AE 0.03 pmol min À1 lg À1 protein (P < 0.01; Fig. 3Ai ,ii). This increase was abolished by the addition of inhibitors of complex I/III of the mitochondrial respiratory chain, i.e. antimycin A and rotenone. This increase in OXPHOS was accompanied by a fourfold increase in the ECAR (1.7 AE 0.1 to 7.1 AE 0.72 mpH min À1 lg À1 protein; P < 0.01) (Fig. 3Bi,ii) . Next, an energy phenotype experiment (Agilent Seahorse Bioscience) was performed without etomoxir to explore whether metabolic changes resulted from inhibition of endogenous FA oxidation (Fig. 3D) . Basally, platelets utilize glycolysis and OXPHOS almost equally (Fig. 3D) . Activation of platelets led to increases in both aerobic glycolysis and OXPHOS (Fig. 3A,B,D) , but, critically, there was a shift to a glycolysis-dominated phenotype (an almost three-fold change in the ECAR), whereby OXPHOS changed only minimally ( Figs 3C and S2B ).
Endogenous reserves can fuel platelet activation
After establishing the importance of glucose metabolism in platelets, we explored the role of endogenous fuels in the absence of exogenous glucose. The omission of glucose from the medium, containing no other energy substrates, had no effect on thrombin-induced platelet aggregation (Fig. 4Ai) or ATP secretion (Fig. 4Aii) , or collageninduced aggregation and secretion (Fig. S2C ), but was accompanied by a significant decrease in the intracellular glycogen level (23.5 AE 4.3 to 10.6 AE 3.5 lg per 10 8 cells) P < 0.05; Fig. 4B ). As externally sourced glucose was not a prerequisite for platelet activation, the relationship between exogenous glucose and endogenous glycogen in thrombin-stimulated platelets was explored (Fig. 4Ci) . In the absence of external sources of energy, thrombin increased the ECAR (from 0.7 AE 0.1 mpH min À1 lg
À1
protein to a maximum of 4.6 AE 0.4 mpH min À1 lg À1 protein; P < 0.001), which was unaffected by oligomycin. In contrast, when replete with exogenous glucose, platelets were able to respond to oligomycin by increasing the ECAR (Fig. 4Cii) . These data suggest that glycogen can support platelet activation, but that glycolytic capacity is diminshed in the absence of exogneous glucose. Consequently, the metabolic fate of glycogen upon platelet activation was explored. In contrast to experiments performed in the presence of external glucose (Fig. 3Ai) , the omission of extracellular glucose and inhibition of b-oxidation caused a sustained and significant fall in the OCR (Fig. 4Di) , suggesting that, in the absence of exogenous glucose, endogenous FAs are critical for maintaining basal OXPHOS. Nevertheless, thrombin (0.1 U mL À1 ) increased the OCR by 2.5-fold (2.1 AE 0.1 pmol min À1 lg À1 protein; P < 0.01) and the ECAR by 10-fold (4.6 AE 1.3 mpH min À1 lg À1 protein; P < 0.01; Fig. 4D ).
Thus, when platelets are deprived of extracellular glucose, thrombin still provokes a switch to a glycolytic phenotype with preserved mitochondrial function, and glycogen has a similar metabolic fate as glucose.
Platelet mitochondrial fuel flexibility
Having established that platelets can take up glucose, but readily utilize endogenous glycogen and FAs in the absence of glucose, we explored the relative flexibility of platelets in oxidizing glucose, endogenous FAs, and glutamine. Flexibility is defined as the difference between the capacity that exists for a given pathway to increase to a maximum capacity and the absolute minimum dependency on that (iii) The average ECAR measured simultaneously with (Di) and plotted over time. (iv) The average ECAR quantified from (Diii). (v) Fold changes in glycogen-dependent OCR and ECAR over basal levels was quantified from (Di) and (Diii). The proportions are calculated for the values that were corrected for non-mitochondrial OCR and non-glycolytic ECAR. Data are expressed as mean AE standard error of the mean, n = 3. *P < 0.05; **P < 0.01; ***P < 0. pathway. We first demonstrated that glutamine contributed minimally to mitochondrial oxygen consumption (Fig. S3A) , leaving glucose and FAs as the main oxidative fuels. Thrombin-induced aggregation was unchanged by UK5099 (an inhibitor of glucose oxidation) or etomoxir when they were used alone or in combination (Fig. 5A ), indicating metabolic plasticity. Next, platelet flexibility in oxidizing glucose at rest and after activation was investigated by measuring the OCR (Fig. 5 ) and the ECAR (Fig. S3) . UK5099 reduced the basal OCR by 36.0% AE 3.5% (Fig. 5Bi) , indicating platelet dependency on glucose oxidation. However, there is the capacity for this to increase to 58.3% AE 2.1% when FA and glutamine oxidation are inhibited (Fig. 5Bii) . The difference between the full capacity and dependency is equivalent to platelet flexibility in glucose oxidation, i.e. 22.2% AE 0.6% of the total OCR (Fig. 5Biii) . In contrast, activation by thrombin (0.1 U mL
À1
) increased platelet dependency on glucose oxidation, accounting for 48.6% AE 3.8% of the total OCR (Fig. 5Ci) . The overall capacity to oxidize glucose did not change from that seen in resting platelets (54.3% AE 1.5% of the total OCR; Fig. 5Cii,iii) , indicating that activation is supported by platelets' ability to utilize metabolic surplus.
Next, platelet flexibility in oxidizing endogenous FAs was measured at rest and after activation. Inhibition of FA oxidation by etomoxir reduced the platelet OCR by 30.63% AE 7.9% (Fig. 5Di) . Subsequent inhibition of glucose and glutamine oxidation indicated that the full capacity of platelets to oxidize FAs was 56.0% AE 7.4% of the total OCR (Fig. 5Dii) . These data indicate that platelets can increase the proportion of the OCR dedicated to FA oxidation by 25.4% AE 6.9% in the absence of other fuels (Fig. 5Diii) . Thrombin (0.1 U mL À1 ) did not have a significant effect on platelet dependency on (37.7% AE 4.0%), capacity for (54.3% AE 1.5%) and flexibility in (23.2% AE 0.5%) FA oxidation (Fig. 5E ) as compared with unstimulated platelets. This may be attributable to the limited pool of metabolically available endogenous FAs. Inhibition of FA and glucose/glutamine oxidation pathways independently did not affect the ECAR. However, inhibition of all major fuel oxidation increased the ECAR significantly (P < 0.05; Fig. S3B ,C). These data indicate that inhibition of oxidation of a single fuel can be compensated for by increased oxidation of the other. Critically, when all fuel oxidation is inhibited, glycolysis is upregulated to compensate for the decreased energy generation.
Mitochondrial function of resting and activated platelets
The fuel flexibility of platelets prompted investigation of platelet functional dependency on ATP from glycolysis and mitochondrial OXPHOS. Inhibition of total mitochondrial ATP synthesis with oligomycin, or inhibition of glucose metabolism with 2-DG, did not affect platelet aggregation. However, almost total inhibition of platelet aggregation was achieved when they were used in combination (Fig. 6Ai,ii) , suggesting that platelets have sufficient glycolysis to support the need for ATP even when the mitochondrial ATP machinery is manipulated. Having established this flexibility, we next performed a detailed analysis of mitochondrial components of respiration in resting platelets. Platelet mitochondrial components of respiration were measured with the sequential injection of oligomycin, to provide the OCR linked to ATP synthesis, FCCP, a mitochondrial uncoupler, which reveals maximal respiration, and a combination of antimycin A and rotenone (Fig. 6Bi) . The ATP-linked OCR, the non-mitochondrial OCR, proton leakage and reserve respiratory capacity were 76.6% AE 5.0%, 11.6% AE 7.0%, 11.7% AE 6.0%, and 34.5% AE 7.0%, respectively (Fig. 6Bii) . Thrombin (0.1 U mL À1 ) increased the OCR from 2.1 AE 0.2 to 3.1 AE 0.4 pmol min À1 lg À1 protein (P < 0.001; Fig. 6Biii,iv) , and this was associated with increased ATP-linked OXPHOS, increased maximal respiration, and increased reserve capacity. Inhibition of platelet-derived TxA 2 generation by indomethacin (10 lM) significantly reduced the thrombin-induced OCR, the ATP-linked OCR, maximal respiration, and reserve capacity (all P < 0.001 as compared with thrombin Non-mitochondrial respiration alone). The omission of glucose did not significantly alter any of the parameters (Fig. 6D) .
Thus, platelets use their reserve respiratory capacity in addition to increasing glycolysis to satisfy the increased need for ATP synthesis in response to thrombin stimulation, which requires platelet-derived TxA 2 to support mitochondrial function (Fig. 6C) . Furthermore, glycogen alone can fully support mitochondrial function during platelet activation (Fig. 6D ).
Discussion
The metabolic fuel choices and how key metabolic pathways are regulated to support platelet functions are unclear. In the present study, we have demonstrated that platelets use both glucose/glycogen and endogenous FAs to support glycolysis and OXPHOS as means of maintaining baseline ATP supply. Upon platelet activation, the cells adopt a glycolytic phenotype regardless of nutrient availability. However, this change to a glycolytic state during cellular activation is underpinned by remarkable metabolic versatility, whereby, under normal physiological conditions, platelets are able to move freely between mitochondrial glucose and FA oxidation.
Glucose is an abundant, readily available nutrient for platelets in situ, but our current understanding of platelet glucose metabolism is limited in terms of the functional requirements for glucose and the glycolytic capacity of platelets under stressed conditions. The abundance of glucose transporter 3 (GLUT3) suggests that sustained glucose transport into platelets is guaranteed even in a low-glucose environment, and is indirectly indicative of the importance of glucose to platelet function, both at rest and following activation [23] [24] [25] . Recent studies have now demonstrated that loss of GLUT3 can fundamentally diminish key elements of platelet function [26] . Thus, focusing on carbohydrate metabolism, we found that platelet glucose uptake was potentially linked to the phase of activation in response to external stimuli. Consistent with this observation, thrombin stimulation caused a receptormediated significant increase in glycolysis. The maximal glycolytic rate of resting platelets was less than that of thrombin-stimulated platelets, which required both PAR1 and PAR4 (Figs 1 and 2) . Activatory cells have a metabolic 'capacity', which enables them to respond quantitatively and sensitively to changing energy demands, despite the fact that, under normal conditions, they operate at a lower metabolic rate [27] . Platelets clearly show this type of glycolytic capacity, as glycolysis increases in response to inhibition of OXPHOS, suggesting a Pasteur effect type of metabolic compensation, and that platelets utilize this 'capacity' to support activation.
Next, we provided a clearer understanding of the biological role of glycogen, and the interplay between glycogen and exogenous glucose and their metabolic fate in platelets. We found that glycogen alone can support platelet activation, and that it had a similar metabolic fate as glucose. Focusing on the partitioning of glucose and glycogen in glycolysis and OXPHOS, our data confirm the findings of previous studies showing that the pathways of glycolysis and glucose oxidation are present in platelets [10, [28] [29] [30] . In addition to this, the current study has reconfirmed that activated platelets adopt a glycolytic phenotype while preserving mitochondrial function, regardless of fuel availability. Importantly, our data have established, for the first time, that this phenotype occurs in the absence of externally supplied glucose, indicating that endogenous reserves can serve as a fuel source (Figs 3 and 4) . These data suggest that the functional responses were driven by choosing aerobic glycolysis over OXPHOS of glucose and glycogen, consistent with a 'Warburg' or aerobic glycolytic phenotype [31, 32] . The commitment to a less efficient energy-generating pathway such as glycolysis is not unusual, and has been reported in granulocytes, dendritic cells [33] , monocytes [34] , and macrophages [35] . Thus, a glycolytic switch upon stimulation observed in blood platelets may represent a conserved immunometabolic pattern in developmentally related cells of blood lineages. Although many nucleated immune cells switch to Warburg metabolism to support proliferation [36] , it is likely that the low efficiency but rapid rate of ATP production by glycolysis is required to support a rapid change in energy demand in response to platelet activation [37] . The preserved mitochondrial function in the presence of a glycolytic phenotype suggests an ATP requirement as well as redox metabolism beyond glycolysis to maintain cell survival [38] [39] [40] .
Glucose metabolism, FA metabolism and amino acid metabolism converge in mitochondria, where fuel oxidation can be modified in response to changes in the availability of nutrients and the energy demand of the cell under various conditions [41] . Focusing on platelet mitochondrial function ( Figs 5 and 6 ), we show that platelets can switch freely between glucose and FA oxidation both at rest and under activated conditions. Earlier studies suggested that FA b-oxidation may compensate for a reduction in glycolysis [42] . However, we show that, when oxidation of glucose and FAs is restricted, platelets upregulate aerobic glycolysis to meet the energy demand for functional responses, indicating not only fuel, but also metabolic pathway, flexibility in order to respond to a thrombotic signal. The majority of oxygen consumed by platelets is linked to ATP synthesis, with only modest contributions from proton leakage and non-mitochondrial functions. Platelet activation leads to increased oxidative metabolism facilitated by the presence of a significant mitochondrial 'reserve capacity', which provides additional scope for the mitochondrial function necessary for responding to increases in ATP demand in times of work or stress [43] . Interestingly, the maximal thrombin-induced OCR required the release of platelet-derived TxA 2 , suggesting that agents secondary to the initial platelet activation are required to promote maximal OXPHOS. The omission of glucose did not affect mitochondrial function, again highlighting the metabolic plasticity of platelets. This suggests the possibility that platelets possess unique metabolic flexibility as compared with other immune cells. For example, inhibition of FA oxidation blocked T-cell differentiation into regulatory T cells, whereas supplementation with FAs supported this [44] . Similarly, the polarization of M 2 macrophages is FA-dependent, and inhibition of FA oxidation drives M 2 macrophages to an M1 state [45] . Mature dendritic cells show both OXPHOS and aerobic glycolysis, and the inhibition of glycolysis prevents dendritic cell maturation [46] . For platelets, such flexibility may be important to ensure that they function in a range of environments, including within the thrombus, where the availability of nutrients and oxygen may be limited [47, 48] . The availability of endogenous glycogen and FAs and the ability to produce sufficient ATP solely from glycolysis or OXPHOS in platelets indicate a potential survival mechanism for the most adverse microenvironments [34, 49] Alternatively, it is possible that flux and the use of specific metabolic pathways are linked to distinct functions. Detailed bioenergetic profiling of platelet immune and angiogenic functions will be required to fully appreciate how the metabolic microenvironment, including the availability of oxygen and nutrients, determines the influence of platelets on multiple aspects of vascular biology. In summary, this article describes a detailed systematic analysis of the fuel choice made by human platelets at rest and under activatory conditions. It is of note that platelets adopt a glycolytic phenotype when stimulated with thrombin, regardless of nutrient availability and the thrombin dose. Most importantly, this study reveals remarkable metabolic plasticity, involving switching freely between substrates and metabolic pathways, of blood platelets under physiological conditions. A better understanding of platelet metabolism and the modulation of fuel availability may offer new opportunities to optimize long-term storage conditions. Moreover, there is increasing evidence showing that the transition between a resting and an activated state of the activatory cells requires specific metabolic patterns [36, 50] to support functional changes [10, 34, 51] . In this context, improving our understanding of platelet metabolism and its regulation could lead to the development of novel therapeutic targets for the treatment of arterial thrombosis and, potentially, other inflammatory diseases.
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